InspireMDSTU:II2 -4.10%42 Buyback Yield % is -119.52 as of Jul. 02, 2026. GuruFocus rates STU:II2 with a GF Score™ of 42/100 and a GF Value™ of €1.53 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 348 Medical Devices & Instruments companies, InspireMD ranks worse than 95.98% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for InspireMD's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:II2 vs TELA, BDMD, PAVM: Buyback Yield % Comparison
For the Medical Devices subindustry, InspireMD's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InspireMD Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InspireMD's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where InspireMD's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InspireMD (STU:II2) has a Buyback Yield % of -119.52 as of Jul. 02, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on InspireMD and its competitors. According to the industry distribution chart, InspireMD ranks #334 out of 348 companies in the Medical Devices & Instruments industry, placing it in the top 96%.
Is InspireMD's Buyback Yield % too high?
InspireMD's current Buyback Yield % is -119.52. Based on the distribution chart, InspireMD ranks #334 out of 348 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, InspireMD has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InspireMD's Buyback Yield % compare to TELA and BDMD?
According to the Medical Devices & Instruments industry distribution chart, InspireMD ranks #334 out of 348 companies for Buyback Yield %. This places InspireMD in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on InspireMD and its competitors. InspireMD's current Buyback Yield % is -119.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InspireMD stock overvalued right now?
Based on GuruFocus' analysis, InspireMD (STU:II2) is currently considered Possible Value Trap. The stock's GF Value™ is €1.53, compared to a current price of €0.59 — trading 61.8% below its estimated fair value. The current Buyback Yield % is -119.52. InspireMD's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For InspireMD (STU:II2), the current Buyback Yield % is -119.52 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InspireMD (STU:II2) Overvalued in 2026?
Based on GuruFocus' analysis, InspireMD stock appears to be undervalued.
The current stock price of €0.59 is trading 61.8% below its estimated GF Value™ of €1.53.
GuruFocus considers InspireMD to be Possible Value Trap.
Key valuation signals for STU:II2:
Buyback Yield %: -119.52
GF Value™: €1.53 vs. price of €0.59 (61.8% below fair value)
No single metric tells the full story. See the STU:II2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
42GF Score
Get the complete analysis for STU:II2
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:II2 has been successfully added to your 
